Introducton
A low bone mineral density (BMD) consttutes the frst diagnostc criterion for osteoporosis, a skeletal metabolic disease further defned by impaired bone microarchitecture, increased bone fragility and susceptbility to bone fractures. The availability of bone density scans as a noninvasive diagnostc technique uncovered the link between this bone disorder and celiac disease (CD) relatvely few years ago. 1, 2 In contrast, the associaton between child osteomalacia and CD has been known since the frst descriptons of the later disease, even before the origin and treatment of CD itself were known. 3 Osteomalacia is a disease characterized by low BMD, marked bone deformites and rickets, which, on rare occasions, is part of the inital presentaton of CD. 4, 5 CD is a highly prevalent disease 6 that afects approximately 1% of the world populaton, according to serology-based screening studies. 7 While CD has been traditonally considered a predominantly childhood-onset disorder, it is now conclusively demonstrated that most patents are diagnosed when adults, as it has also been corroborated in Spain 8, 9 , among whom both atypical manifestatons and a low suspicion index may delay the diagnosis. 10 In fact, most of those who sufer from CD are undiagnosed and women are more frequently diagnosed than men. Many current CD patents lived with their symptoms for years before diagnosis and were therefore exposed to the consequences of the disease. Furthermore, osteoporosis presents characteristcs similar to those of CD in terms of frequency and underdiagnosis. It has been hypothesized that CD could explain part of the considerable "mixed bag" represented by idiopathic osteoporosis. 1, [6] [7] [8] [9] [10] [11] Therefore, there is a high rate of suspicion among health professionals treatng both diseases (CD and osteoporosis) and using their expertse could bring many hidden cases to light, with the beneft of an accurate and early treatment.
In adult patents, changes in bone mineralizaton, osteopenia or osteoporosis are some of the most common CD complicatons and can afect up to 75% of the patents as shown in a few series of studies 1 with a prevalence among celiac suferers that doubles that of the unafected populaton in the same age range. 11 Despite this, the many studies on the subject notwithstanding, a descripton of how CD (a primarily digestve disorder) can afect bone metabolism has yet to be fully elucidated.
CD in itself causes signifcant deterioraton in the quality of life 11, 13 , which is compounded by the presence of osteoporosis and its clinical manifestaton in the form of fractures. These and other factors are the reasons why physicians adopt an interventonist stance and try to prevent its occurrence and/or mitgate its impact.
together under the term "bone quality." These include microarchitecture, bone turnover degree, build-up of lesions or microfractures and bone mineralizaton degree. 16 The World Health Organizaton establishes diferent low bone mass degrees based on bone density scan measurements of any skeletal area in American Caucasoid women. 17 This strategy establishes an osteoporosis diagnosis when bone mass values are below -2.5 standard deviatons (SD) of peak bone mass (i.e. the maximum BMD value reached by an adult) and an osteopenia diagnosis when those values are located between -1 SD and -2.5 SD. Severe or established osteoporosis is that presentng with a BMD less than -2.5 SD and a current or past fragility fracture. 15, 18 The results of BMD measurements are expressed as a T-score, which is the number of standard deviatons by which BMD measurement difers from bone density measurement in the young populaton ("peak" BMD) ( Table 1 ). Another way of expressing the results is the Z-score, which is obtained by comparing a BMD measurement with reference values for subjects of the same age and gender. It is recommended in some guidelines 22 for men and for premenopausal women.
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Prevalence of osteoporosis among celiac disease patents
It is estmated that by the tme childhood CD is diagnosed, one-third of afected children have osteoporosis, one-third have osteopenia and only the remaining third retain a normal BMD. 9 In any case, once the gluten-free diet (GFD) is insttuted, most celiac children catch up to their height-weight growth curve and accelerate their rate of bone mineralizaton, so that most achieve normal peak bone mass by the tme bone growth is completed. The main problem arises when CD is diagnosed during adulthood, once bone growth is complete and peak bone mass has been reached. Among these patents, the prevalence of osteoporosis is at least twice that of the unafected populaton in the same age range. 6, 20 More than half of asymptomatc celiac patents with positve serological and digestve tract markers may have bone disease at the tme of diagnosis. 1, 10, [21] [22] [23] [24] [25] This also includes those without villous atrophy, that is, those who are at stages 1 and 2 of the Marsh-Oberhüber duodenal lesion classifcaton.
Prevalence studies of bone mass loss among CD patents reveal widely variable frequencies 2, 21, [26] [27] [28] [29] [30] [31] [32] [33] ( Table 2) ; Valdimarsson et al. carried out a prospectve study of 63 adult patents and noted a prevalence of osteoporosis of 22% in the forearm, 18% in the hip and 15% in the lumbar spine (estmated on the basis of Z-scores). 34 Bardella et al only documented low BMD among women diagnosed with CD during adulthood. 35 Meyer et al. found low BMD in the lumbar spine in 38% and in the hip in 44% of the adult celiac patents analyzed. 33 The wide variability in the frequency of low BMD in these studies may be explained by several factors, including the diagnostc criteria for osteoporosis (T or Z-score), the measurement method, the skeletal locaton where the measurement was obtained, patent selecton and whether assessment was performed before or afer a GFD was started. In any case, the available data confrm a clearly heightened prevalence of low BMD among celiac patents compared to the general populaton, which generally ranges around 40%.
Low BMD has been demonstrated in patents with classic symptoms 11 , in sub-clinical cases 36 and even in asymptomatc patents. 26 Paradoxically, an even greater impairment has been observed among patents without digestve symptoms than among those with classic symptoms. 10 Therefore, the type of CD-related symptom does not seem to predict the presence of low BMD, which explains atempts to identfy other causes.
Osteoporosis is therefore a common CD complicaton, which suggests that it is appropriate to consider whether or not to screen for CD in patents with idiopathic osteoporosis. Although there is no defnitve consensus, the majority of opinions are in favor of this strategy 37, 40 , as CD frequency is 10 tmes higher than expected in patents with osteoporosis; in fact, a similar CD frequency among type 1 diabetcs already justfes universal screening among the later. 41 Moreover, CD screening through specifc antbodies in patents with OS has led to the diagnosis of between 4 42 and 17 40 tmes more celiac patents.
Those studies where the results were opposed to screening for CD among osteoporosis patents can be explained due to the use of low-sensitvity antbodies; in fact, Legroux-Gerot et al. only measured ant-gliadin antbodies, while tssue ant-transglutaminase (AAtTG) was only determined in those with positve tters 43 , a strategy that underdiagnoses CD. This same study established the AAtTG positvity threshold at 50 U/mL, well above the 2 U/mL threshold currently recommended for diagnosing adults. 
Aetology and pathogenesis of low BMD in CD
The pathogenic mechanisms underlying metabolic bone disease in patents with CD have not been fully elucidated. The origin of osteoporosis in CD has been classically associated with malabsorpton of calcium and vitamin D 46 caused by intestnal villous atrophy 47 , as well as by secondary hyperparathyroidism. 48 Low consumpton of dairy products 51 , failure to ever reach peak theoretcal bone mass 26, [49] [50] , a higher degree of duodenal injury in biopsies 51, 52 and a greater diagnostc delay 20 have also been directly related to the pathogenesis of low BMD in celiac patents.
We know that vitamin D defciency is common among patents with CD, although there are no changes in vitamin D receptor expression 53 nor is there a greater number of receptor gene mutatons interfering with the metabolism of this vitamin 54 in this populaton. Restricted milk intake may exacerbate vitamin D defciency; in fact, co-occurrence of lactose intolerance is common among celiac patents and it is estmated at 10%, but may increase to 50% in the presence of obvious malabsorpton symptoms. [55] [56] [57] [58] However, one must bear in mind that diet only provides 5-10% of required vitamin D 59 , the rest being obtained from exposure to sunlight. Even so, studies of celiac patents have failed to establish any clear associaton between vitamin D levels and bone impairment. This is also the case for other intestnal diseases, such as infammatory bowel disease. 59 Several authors have suggested that defcits of other fat-soluble vitamins (A, K and E) and even in water-soluble vitamins (C, B12, folic acid and B6) or of minerals (such as iron, calcium, phosphorus, copper, zinc, boron, fuorine), which are required for normal bone metabolism 52, 60 , also result from the intestnal malabsorpton exhibited by celiac patents.
Hyperparathyroidism is another implicated factor; even in patents with normal vitamin D serum levels, high PTH levels have been associated with bone mass loss. 47 Indeed, celiac patents on a GFD frequently exhibit high serum PTH levels. 61 Reduced serum levels of IGF-1 (insulin-like growth factor-1 or somatomedin C) 62 consttute an additonal hormonal factor which has been involved in patents with a lower bone mass. This was associated with decreased zinc serum levels 63 , which became normal afer introducing a GFD.
Despite all of the above, the malabsorpton theory in and of itself has not been corroborated by some studies 52 , while the complex regulaton of bone turnover and the efect of the multple nutritonal factors involved, together with the discordant results of various studies, have led to the emergence of new hypotheses for the origin of osteoporosis in CD, such as the link between low BMD and chronic infammaton. 64 Indeed, a less well-known functon of vitamin D is its role in the actvaton of the T lymphocytes that maintain the integrity of intestnal mucosal immunity, prevent infecton 65 and regulate protein binding. 66 Accordingly, vitamin D defciency has long been considered to be a trigger of autoimmune and infammatory diseases. 67 Chronic infammaton determines changes in bone metabolism via several proinfammatory cytokines, such as tumour necrosis factor alpha (TNF-α), interleukins (IL)-1beta, IL-6 or gamma interferon. TNF-related cytokines include the receptor actvator of nuclear factor kappa-B (RANK), its ligand (RANKL), and osteopreotegerin (OPG). RANKL is a key molecule in the regulaton of bone metabolism; its genetc expression is induced afer actvaton of T lymphocytes and it is secreted by these cells. RANKL has proved to be a survival factor whose primary functon is actvaton of osteoclasts, cells involved in bone resorpton. 68 Overproducton of RANKL is implicated in a variety of degeneratve diseases of bone tssue, such as rheumatoid arthrits or psoriatc arthrits, while RANKL gene inactvaton in mice produces severe osteopetrosis caused by a massive osteoclast defcit. 69, 70 Conversely, OPG (osteoprotegerin, for bone protecton) is an osteoclastogenesis-inhibitng protein, which acts as a decoy receptor homologous to RANK, binds to its ligand RANKL, and thereby neutralizes its acton. 71 OPG producton is stmulated in vivo by oestrogens and by the ant-resorptve drug strontum ranelate. 72 IL-6 promotes the expression of both RANKL and OPG and stmulates both osteoblast formaton and bone resorpton.
Serum levels of RANKL and OPG are elevated in patents with CD 73 and the relatve relatonship established between these cytokines is therefore more important than their actual levels; hence, an imbalance in the OPG/RANKL rato has been associated with altered bone turnover in patents with diferent conditons, including renal osteodystrophy 74 , rheumatoid arthrits 75 , Cushing's disease 76 and primary biliary cirrhosis. 77 The OPG/RANKL rato is directly associated with IL-6 serum levels 73 and lumbar bone mass. 78 Thus, adult women with CD have OPG/RANKL ratos signifcantly lower than controls despite adherence to a GFD; this correlates with a lower lumbar BMD. 79 Although the role of high OPG levels in CD has not been fully elucidated, the available evidence suggests that this is a protectve mechanism against other factors that cause bone damage. The mechanisms described as direct actvators of osteoclastogenesis and subsequent bone mass loss 80 have recently been recognized as potental contributors to osteoporosis among patents with a range of digestve diseases. In fact, patents with CD and infammatory bowel disease have similar profles in terms of expression of bone metabolism regulatory cytokines. 81, 83 Finally, the aetology of osteoporosis in CD defnitely includes factors shared with the rest of the populaton 84 (family history, age, menopause, physical actvity, smoking), as well as other specifc factors such as genetc infuence, the above-mentoned vitamin defciencies, hormonal changes and the infammatory process itself.
Years of exposure to dietary gluten before diagnosis do not seem to infuence BMD signifcantly 26, [32] [33] [85] [86] nor does early menopause. 24 Some studies report an inverse relatonship between GFD and calcium intake. 87 There is litle data on the infuence of patent gender on BMD, but most studies show no diference in this regard. 24, [33] [34] [88] [89] Another factor associated with poor bone conditon is a low body mass index (BMI). 11, 52, 84, 90 Patents with persistent villous atrophy despite proper adherence to the GFD (refractory CD) are partcularly susceptble to osteoporosis, with a prevalence of 58% compared to 22% reported among GFD-responsive patents. 90 
Diagnosis of low bone mineral density in CD
All patents in whom there is clinical suspicion of osteoporosis should undergo a thorough recording of their history and a physical examinaton so as to identfy other risk factors and/or consequences. As for imaging methods, conventonal radiography has not proven to be a specifc or sensitve method for assessment of changes in bone mass; therefore, osteoporosis studies should be performed using bone density scans. In the case of CD, it has been suggested that all patents diagnosed in adulthood should undergo bone densitometry 11, 91 as it is a simple, noninvasive and highly accurate 92 diagnostc method (its margin of error is estmated at only 5-6%). Its greatest beneft is determining whether there is osteoporosis and the degree of impairment so that a treatment regimen can be planned. However, some studies, observing the low risk of bone fracture among celiac patents, have questoned the usefulness of routne bone density scan 28, 93 as it is considered to have low cost-efectveness. Other authors suggest using densitometry only in patents with digestve conditons 94 , even though this is not a conditoning factor for greater risk. 95 In fact, celiac patents without gastrointestnal symptoms may have low BMD, which increases afer start of the GFD. 10 Recent studies advocate densitometric assessment in all celiac patents diagnosed during adulthood who have villous atrophy on duodenal biopsies and/or laboratory values suggestve of malnutriton or malabsorpton, regardless of their symptoms. 52 Another issue raised in the literature concerns the optmal tming for bone density scan in celiac patents; whether at the tme of CD diagnosis or afer a period of adherence to the GFD. In fact, celiac children show a great bone recovery capacity afer startng a GFD, so no further studies seem to be necessary untl their growth period is completed. In any case, the main beneft of BMD testng would be obtained when the introducton of a diferent treatment rather than the GFD alone is derived from test results.
As the development of osteoporosis is determined by multple risk factors, identfying which of these factors are most relevant, or using a score for the risk of fracture at 10 years, is highly desirable. Bone remodelling markers (such as the N-terminal telopeptde of procollagen-1, hydroxyproline, and bone alkaline phosphatase) provide additonal informaton on the dynamics of bone turnover that is complementary to densitometry fndings. In celiac patents with osteoporosis, levels of these markers are higher than in celiacs with normal BMD. 52 However, the usefulness of their determinaton in bone disease diagnosis is limited, so this measurement is not recommended as part of the routne evaluaton of the patents with osteoporosis.
Bone fracture risk in CD
Due to the increased prevalence of osteoporosis, celiac patents have a high risk of fractures, estmated at between 3.5 to 7 tmes higher than that of the unafected populaton of the same age and gender. 11 Furthermore, up to one in four adult CD patents have an established history of fractures 96 , which produces signifcant deterioraton in the quality of life.
As in other aspects of the relatonship between CD and osteoporosis, quantfcaton of fracture risk by diferent studies shows mixed results. These discrepancies are largely due to the way in which the data were collected; mainly from fracture reports, questonnaires, or hospital admissions. It is therefore possible that the prevalence of fractures (vertebral, hip, and overall) is underestmated in the celiac populaton. One of the common issues of fracture risk studies is that they lack proper morphometric assessment of the spine, which underestmates fractures at that level 2 , or failure to use validated questonnaires or methods, such as the FRAX® (Fracture Risk Assessment Tool) index proposed by the World Health Organizaton. 97 To date, nine published studies and one meta-analysis have estmated the incidence or prevalence of bone fractures in the adult celiac populaton (Table 3) . 28 Their heterogeneous methodologies, use of diferent cut-of points for determinaton of osteoporosis and variable diagnostc criteria for CD translate into signifcant discrepancies in results. A retrospectve study conducted in Argentna on 165 celiac patents determined a peripheral fracture prevalence over 3 tmes higher than that observed in controls. 2 The same study showed that the highest prevalence of fractures in the lumbar spine was only present in patents with CD classic symptoms. 98 A retrospectve study carried out in the UK showed that 21.3% of celiac patents had a history of fractures, compared with only 2.7% of non-celiac controls, a highly signifcant diference quantfed as a relatve risk (RR) of 7.0. 102 By contrast, other studies with large sample sizes in the same geographical region found no major diferences. 29 Two further studies in Europe, the frst with a large number of the patents, reported a slight increase in risk of fracture: a study of approximately 13,000 patents and 65,000 controls in Sweden showed a 2.1% higher risk (95%CI: 1.8-2.4) of hip fracture and a 1.4% higher risk (95%CI: 1.3-1.5) of any type of fracture among celiacs. 31 A recent study of adult celiacs in Spain, conducted at the tme of diagnosis, used the FRAX® tool to estmate the risk of fracture at 10 years. This showed a moderate risk of fracture among patents with duodenal villous atrophy (Marsh stage III), which was 3.5 tmes that of the patents without villous atrophy (Marsh stage I or II). 52 Finally, the Olmos et al. meta-analysis 101 , which included 21,000 celiac patents and about 100,000 controls, confrmed a 43% increase in the prevalence of fractures among celiacs (8.7% vs. 6.1%). CD, celiac disease; OR, odds rato; RRI, relatve risk increase; HR: hazard rato.
Treatment of low bone mineral density in patents with CD
The frst-line treatment for osteoporosis in CD is the GFD itself: many studies have demonstrated its efect on bone density and calcium absorpton. 21, [23] [24] 27, 32, 87, 90, 102, 105 The greatest bone mass gain described in these studies is during the frst year: 24, 34 The GFD leads to a 5% increase in bone mass afer 1 year 1 , although this is not enough for bone mass to normalize. In clinical practce conditons, the degree of adherence to the GFD also determines the recovery of bone mass, which is generally estmated at around 30%. 106, 107 Furthermore, the recovery rate is higher in young celiac patents 21 than among adults, 21, 34 which is largely explained by the fact that 97% of bone mass is gained in the frst two decades of life and full recovery is difcult afer this tme.
BMD loss associated with pediatric CD responds to GFD contnuously and gradually, with almost complete restoraton of bone mass afer about two years' treatment. 108 The earlier the age at which the GFD is started, the beter and faster the response. 26 In fact, it is estmated that an increase in BMD will only take place if the GFD is started before the age of 25.
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A proper GFD is so important for bone metabolism that lack of improvement in BMD afer its introducton has been associated with persistent duodenal lesions.
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In additon to the GFD and in accordance with the NIH consensus statement on the treatment of osteoporosis, 15 an adequate daily intake of calcium and vitamin D should be ensured, as it is a critcal factor for bone mass acquisiton and maintenance. Untreated adult celiac patents have shown a 45% reducton in calcium absorpton followed by an improvement of 52% afer 6 months of adherence to the GFD. 109 Regarding vitamin D, at the tme of diagnosis, less than 5% of Spanish adult CD patents had normal serum levels. 52 A daily intake of 1200-1500 mg calcium and 400 U vitamin D is recommended and, as in all other forms of osteoporosis, this should be supplemented with medicatons. Adherence to drug therapy, as to the GFD, is a crucial aspect of treatment, so patents must be kept motvated. In fact, these patents will most commonly abandon treatment with calcium and vitamin D, as it must be taken daily, while hormonal therapy and bisphosphonates (which are administered weekly) are usually adhered to correctly. 110 Drug treatment would be indicated for patents who do not achieve bone mass recovery goals and would not difer from that established for other causes of osteoporosis, with bisphosphonates being the recommended frst-line therapy. However, the literature is lacking in data on the specifc efect of bisphosphonates on CD-associated osteoporosis.
Conclusions
CD has been associated with low BMD since its very frst descriptons. Osteomalacia in children with CD is now an exceptonally rare fnding; unfortunately, the same cannot be said for osteoporosis and osteopenia, which occur in 40% of the patents diagnosed in adulthood and determine a variable increase in the risk of bone fracture, leading to lower quality of life. Changes in the epidemiology of CD make low BMD screening by bone density scans more relevant for adult celiacs. Subjects with villous atrophy or laboratory values suggestve of malnutriton at the tme of CD diagnosis may derive greater beneft from bone density scan.
The gluten-free diet is also the basis of low BMD treatment among celiacs and it is sufcient in younger patents. In adults with low bone mass, however, it must be supplemented with calcium and vitamin D. Although specifc studies are lacking, bisphosphonates might also provide an efectve frst line of treatment for adult celiac patents with osteoporosis.
